Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00055521" target="_blank" >RIV/00216224:14110/11:00055521 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3324/haematol.2011.042937" target="_blank" >http://dx.doi.org/10.3324/haematol.2011.042937</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2011.042937" target="_blank" >10.3324/haematol.2011.042937</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis.

Popis výsledku v původním jazyce

Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-timequantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold,

Název v anglickém jazyce

Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis.

Popis výsledku anglicky

Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-timequantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hematologica - The Hematology Journal

ISSN

0390-6078

e-ISSN

—

Svazek periodika

96

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

1815-1821

Kód UT WoS článku

000298544400015

EID výsledku v databázi Scopus

—